Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is a deadline of August 25, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after the company disclosed that EU authorities requested a review of the death, the stock price dropped by $4.18, or 7.13%, closing at $54.43 [6]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24, or 42.12%, closing at $20.91 [7][8]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52, or 8.01%, closing at $17.46 [8][9]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Apple iPhone sales in China rose in the second quarter of the year for the first time in two years, Counterpoint Research said, as the tech giant looks to turnaround its business in one of its most critical markets.Sales of iPhones in China jumped 8% year-on-year in the three months to the end of June, according to Counterpoint Research. It's the first time Apple has recorded growth in China since the second quarter of 2023.Apple's performance was boosted by promotions in May as Chinese e-commerce firms dis ...

Core Insights - IREN Limited has announced the purchase of 2,400 next-generation NVIDIA Blackwell B200 and B300 GPUs for approximately $130 million, fully funded from existing cash, while also exploring financing options for AI Cloud Services growth [1][2][4] - The new GPUs will be installed at IREN's Prince George, BC campus, increasing the total fleet to around 4,300 NVIDIA GPUs, with the capacity to host over 20,000 Blackwell GPUs due to 50MW of dedicated power [2][3] - The Blackwell architecture enhances performance and efficiency, positioning IREN as a leading cloud provider in a supply-constrained market, with rising demand from AI-native enterprises and cloud operators [3][4] Company Positioning - IREN's vertically integrated platform, supported by 2,910 MW of grid-connected power, allows for flexible, end-to-end solutions across the AI infrastructure stack, including powered shells and fully managed cloud services [4][9] - The investment in Blackwell GPUs is expected to yield attractive risk-adjusted returns and support ongoing discussions in IREN's AI Data Center business [4][5] - IREN operates in renewable-rich regions and focuses on high-performance computing solutions, including AI Cloud Services and Bitcoin mining, leveraging 100% renewable energy [9][10]

订阅美联储动态 +订阅 跟踪全球贸易动向 +订阅 美国财长警告 关税可能会回升至4月2日水平 金十数据7月3日讯，美国财长贝森特警告美国的贸易伙伴不要延长贸易谈判，称如果没有取得进展，关 税可能会回升到4月2日的水平。贝森特透露，他今天将与欧盟谈判代表会面。当被问及讨论的结果时， 他只是说，"我们将看看与欧盟会发生什么。"在美国债务问题上，贝森特表达了对市场需求的信心。他 称"对美国国债的需求很大，"国内外对美国国债的需求依然强劲。他将债务管理过程描述为"有条不 紊"。贝森特还对利率发表了评论，暗示"两年期国债告诉你隔夜利率过高"，且"通胀预期应该会回 落"。他批评了美联储，称该委员会的判断"似乎有点偏差"。关于美联储的运作，贝森特表示，"对美联 储来说，控制开支是有益的"，他希望"看到美联储合理调整预算规模"。当被问及他是否希望美联储主 席鲍威尔辞职时，贝森特拒绝给出具体回应。他指出，有"很多强有力的美联储主席候选人"，并提到 了"明年填补两个美联储董事会职位"的可能性。 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In 3D Systems To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in 3D System between August 13, 2024 and May 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PR ...

Clinical Trial Results - MeiraGTx's rAAV8.hRKp.AIPL1 gene therapy has shown efficacy in all 11 children (aged 1-4 years) treated for AIPL1 Retinal Dystrophy (LCA4) [3] - In the unilateral treatment group (4 patients), durable efficacy has been observed for up to 4 years [3] - In the unilateral treatment group, visual acuities of treated eyes improved to a mean of 0.9 LogMAR, while untreated eyes showed no improvement [6] - All 7 bilaterally-treated children showed meaningful improvements in functional vision, visual acuity, and neurophysiology [14] - Binocular visual acuities in bilaterally-treated children improved to a mean of 1.0 LogMAR after a mean follow-up of 5 months [14] Regulatory Status - MeiraGTx was granted an Innovation Passport designation in the UK for rAAV8.hRKp.AIPL1 [16] - MeiraGTx has been advised to file for 'Marketing Authorization Under Exceptional Circumstance' in the UK based on data from 11 children [16] - AAV-AIPL1 has orphan status in the US and EU and Rare Pediatric Disease Designation in the US, making it eligible for a PRV voucher upon approval [16] Overall Impact - Treatment with rAAV8.hRKp.AIPL1 has resulted in improvements in visual function, retinal function, and visual behavior in treated children [15] - These visual improvements have led to life-changing benefits in communication, behavior, schooling, mood, psychological well-being, and social integration [15]

Core Viewpoint - Beijing Tongrentang Medical Investment Co., Ltd. (Tongrentang Medical) has submitted its IPO application for the third time in a year, aiming to become the fourth listed company under the Tongrentang Group, which includes Tongrentang, Tongrentang Technology, and Tongrentang Guoyao [1][8] Company Overview - Tongrentang Medical, established in 2015, is the largest private traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of outpatient and inpatient visits in 2024 [1] - The company ranks second in the private traditional Chinese medicine medical service industry with a market share of 0.2% in total medical service revenue, accounting for 46.5% of the market size of the traditional Chinese medicine medical service industry in China [1] Financial Performance - Revenue from Tongrentang Medical has shown growth from approximately 911 million yuan in 2022 to 1.175 billion yuan in 2024, with net profits turning positive in 2022 after a series of acquisitions [3][4] - The company reported net profits of -9.23 million yuan in 2022, 42.63 million yuan in 2023, and 46.19 million yuan in 2024 [3] Acquisition Strategy - The company's growth has been primarily driven by acquisitions, with plans to acquire five profit-making medical institutions by the end of 2029, focusing on economically active regions such as Beijing and the Yangtze River Delta [5][8] - Tongrentang Medical has increased its total number of medical visits from 1.3 million in 2022 to 3 million in 2024, with a compound annual growth rate of 51.9% [4] Debt and Financial Risks - The company's debt ratio has risen significantly from less than 10% in 2021 to 45.2% in 2024, raising concerns about the sustainability of its growth [2][7] - As of April 30, 2024, the total outstanding bank loans amounted to 142 million yuan, with a significant portion of its equity pledged to secure financing [7] Market Position and Competition - The number of participants in China's private traditional Chinese medicine medical service industry has increased from 2,525 in 2019 to 3,614 in 2024, indicating intensified competition [9] - Despite the competitive landscape, Tongrentang Medical benefits from the strong brand recognition of the "Tongrentang" name and has a well-established business model that includes medical services, management services, and health product sales [9] IPO Objectives - The funds raised from the IPO are intended for expanding the company's medical service network, enhancing service capabilities, repaying bank loans, and general corporate purposes [8] - The repeated submissions of the IPO application may indicate challenges in meeting market expectations or regulatory requirements [8]

"这周末快40度了，空调能提前送货安装吗？"家住江苏省南京市的秦女士即将入住新房，在苏宁易购购 买的2台空调原计划7月中旬才送货安装，而提前到来的高温让她措手不及，只能求助于专属"蓝朋友"。 苏宁易购家电管家王娇娇第一时间沟通协调物流仓库及帮客工程师，第二天即完成了两台空调的送货及 安装调试。"最近一周到店选购空调的顾客比之前多了一倍还不止，通过门店仓库联动，今天下单明天 就能送货，最快24小时就能让顾客用上空调，V4、V5会员还可获得一次空调免费清洗服务。"王娇娇 说。 7月2日，国家疾病预防控制局联合中国气象局发布首个全国高温健康风险预警，多地亮起代表"极高风 险"的红色警报。未来一周，华北南部、黄淮至江南、华南的大部地区都将体验"蒸桑拿"，山东、河 南、安徽、江苏、湖北、浙江等地还可能出现40℃及以上的酷热天气。多地夜间最低气温仍达30℃左 右，形成全天候的高温"围攻"之势。 持续高温点燃清凉家电消费，空调换新、清洗需求加速释放。苏宁易购清凉节推出爆款空调一口价，叠 加国补、厂补、苏宁补多重优惠后至高立省50%，其中1.5匹一级能效变频空调低至1599元，3匹客厅风 管机低至3999元。以旧换新单台空调 ...

据南京发布消息，首份"苏超"赛事影响力报告出炉。7月1日，从国家统计局江苏调查总队获悉，近期国家统 计局江苏调查总队对全省3189位常住居民开展的专题调研显示，江苏省城市足球联赛成功收获群众的关注度 与美誉度。赛事影响力与刺激消费互促共振。 香港特区政府公布"粤车南下"初步实施阶段，每日配额100辆车 香港特区政府7月2日公布"粤车南下"将于今年11月实施。香港特区政府运输及物流局局长陈美宝2日宣布， 经与广东省相关部门协商后达成共识，"粤车南下"计划争取于11月正式启动实施。初步实施阶段，每日配额 100辆车，车辆可驶入香港市区。 8月1日起，现金买黄金钻石超10万元需上报 7月2日消息，央行近日印发《贵金属和宝石从业机构反洗钱和反恐怖融资管理办法》（下称《管理办法》） 称，客户单笔或者日累计金额人民币10万元以上(含10万元)或者等值外币现金交易的，从业机构应当按照规 定在交易发生之日起5个工作日内向中国反洗钱监测分析中心提交大额交易报告。该办法自8月1日起施行。 全国首个！"无堂食外卖"标准来了 "苏超"赛事影响力报告：赛事经济成为激发城市消费活力的新引擎 近日，重庆市市场监管局制定发布了《无堂食外卖经 ...